Half-year report · Q2
9265.TEDINET S100V29Y
Period2024-06-01 → 2024-11-30
Filed2025-01-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥31.4bn | 2024-06-01 → 2024-11-30 | Cons. | Net sales |
| Revenue | ¥61.6bn | 2023-06-01 → 2024-05-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥28.9bn | 2023-06-01 → 2023-11-30 | Cons. | Net sales |
| Operating income | ¥522m | 2024-06-01 → 2024-11-30 | Cons. | Operating income |
| Operating income | ¥618m | 2023-06-01 → 2023-11-30 | Cons. | Operating income |
| Ordinary income | ¥552m | 2024-06-01 → 2024-11-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.0bn | 2023-06-01 → 2024-05-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥645m | 2023-06-01 → 2023-11-30 | Cons. | Ordinary income |
| Profit before tax | ¥586m | 2024-06-01 → 2024-11-30 | Cons. | Income before income taxes |
| Profit before tax | ¥700m | 2023-06-01 → 2023-11-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥338m | 2024-06-01 → 2024-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥580m | 2023-06-01 → 2024-05-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥480m | 2023-06-01 → 2023-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥337m | 2024-06-01 → 2024-11-30 | Cons. | Profit loss |
| Net income | ¥477m | 2023-06-01 → 2023-11-30 | Cons. | Profit loss |
| Total assets | ¥26.4bn | at 2024-11-30 | Cons. | Assets |
| Total assets | ¥26.6bn | at 2024-05-31 | Cons. | Assets |
| Total assets | ¥24.8bn | at 2023-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥17.7bn | at 2024-11-30 | Cons. | Liabilities |
| Total liabilities | ¥18.0bn | at 2024-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥8.7bn | at 2024-11-30 | Cons. | Net assets |
| Net assets / equity | ¥8.6bn | at 2024-05-31 | Cons. | Net assets |
| Net assets / equity | ¥8.3bn | at 2023-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.4bn | at 2024-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥5.3bn | at 2024-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥4.4bn | at 2024-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.3bn | at 2024-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.0bn | at 2023-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.8bn | at 2023-05-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥633m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥878m | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥544m | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥19m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.1bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥154m | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥239m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥335m | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥123m | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥136.8 | 2024-06-01 → 2024-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥227.96 | 2023-06-01 → 2024-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥188.05 | 2023-06-01 → 2023-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 32.9% | at 2024-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.2% | at 2024-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.5% | at 2023-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-06-01 → 2024-11-30 | ¥0 |
| Reconciling Itemsreconciling | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥0 |
| Reconciling Itemsreconciling | segment profit | 2024-06-01 → 2024-11-30 | −¥519m |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥113m |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥112m |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥0 |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | segment profit | 2024-06-01 → 2024-11-30 | −¥82m |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥31.2bn |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥31.2bn |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥0 |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥1.1bn |
| jpcrp040300-q2r_E33393-000Medical Mallreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥35m |
| jpcrp040300-q2r_E33393-000Medical Mallreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥35m |
| jpcrp040300-q2r_E33393-000Medical Mallreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥0 |
| —segment total | revenue | 2024-06-01 → 2024-11-30 | ¥31.4bn |
| —segment total | revenue external | 2024-06-01 → 2024-11-30 | ¥31.4bn |
| —segment total | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥0 |
| —segment total | segment profit | 2024-06-01 → 2024-11-30 | ¥1.0bn |
| Reconciling Itemsreconciling | revenue | 2023-06-01 → 2023-11-30 | ¥0 |
| Reconciling Itemsreconciling | revenue intersegment | 2023-06-01 → 2023-11-30 | ¥0 |
| Reconciling Itemsreconciling | segment profit | 2023-06-01 → 2023-11-30 | −¥494m |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥146m |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥146m |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue intersegment | 2023-06-01 → 2023-11-30 | ¥0 |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥6m |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥28.7bn |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥28.7bn |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | revenue intersegment | 2023-06-01 → 2023-11-30 | ¥0 |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥1.1bn |
| jpcrp040300-q2r_E33393-000Medical Mallreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥36m |
| jpcrp040300-q2r_E33393-000Medical Mallreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥36m |
| jpcrp040300-q2r_E33393-000Medical Mallreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥2m |
| —segment total | revenue | 2023-06-01 → 2023-11-30 | ¥28.9bn |
| —segment total | revenue external | 2023-06-01 → 2023-11-30 | ¥28.9bn |
| —segment total | revenue intersegment | 2023-06-01 → 2023-11-30 | ¥0 |
| —segment total | segment profit | 2023-06-01 → 2023-11-30 | ¥1.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 485
| Item | Context | Value | Unit |
|---|---|---|---|
| Name major shareholders | CurrentQuarterInstant_No9MajorShareholdersMember | Original text (Japanese)小沼 滋紀 | |
| Address major shareholders | CurrentQuarterInstant_No9MajorShareholdersMember | Original text (Japanese)千葉県野田市 | |
| Name major shareholders | CurrentQuarterInstant_No10MajorShareholdersMember | Original text (Japanese)株式会社ＥＰＡＲＫ | |
| Address major shareholders | CurrentQuarterInstant_No10MajorShareholdersMember | Original text (Japanese)東京都港区芝浦４丁目16－25 | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)ヤマシタヘルスケアホールディングス株式会社 | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)福岡県福岡市博多区下川端町２番１号 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Type1 semi annual consolidated financial statements financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated statement of cash flows (text) | CurrentYTDDuration | Text · Plus | |
| Major components of selling general and administrative expenses (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding reversal of allowance for doubtful accounts (text) | CurrentYTDDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |